PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality

PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality

IntroductionPoly(ADP-ribose) polymerase (PARP) is a nuclear enzyme involved in the repair of DNA single-strand breaks (SSB). The recent development of poly(ADP-ribose) polymerase inhibitors (PARPi) results from over 45 years of studies. When the activity of PARP1 or PARP2 is compromised, DNA SSB les...

Full description

Bibliographic Details
Main Authors: Vasily A. Yakovlev, Stephanie A. Sullivan, Emma C. Fields, Sarah M. Temkin
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
AKT1
ARID1A
homologous recombination repair
ionizing radiation
non-homologous end joining repair
ovarian clear cell carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1124147/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1124147/full

Similar Items